Journal
DRUG DESIGN DEVELOPMENT AND THERAPY
Volume 7, Issue -, Pages 893-903Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S32331
Keywords
sitagliptin; CKD; chronic kidney disease; renal impairment
Categories
Funding
- Abbott
- Astra-Zeneca
- Boehringer Ingelheim
- BMS
- Diartis
- Eli Lilly
- GlaxoSmith-Kline
- Merck Sharp Dohme
- Novartis
- Novo Nordisk
- Pfizer
- Roche
- Sanofi-aventis
- Schering-Plough
- Servier
- Takeda
Ask authors/readers for more resources
Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving beta-cell function and glycemic control, and also is used in special circumstances like chronic kidney disease, with appropriate dose reductions. Overall, cardiovascular outcomes are no different from other oral hypoglycemic agents. In this review article we have summarized all the previous studies relevant to sitagliptin use in clinical practice and emphasized its use in various stages of chronic kidney disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available